Autopsy report · NCT00936234

Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).

“insufficient recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2, Phase 3

Sponsor

Johann Wolfgang Goethe University Hospital

Sponsor type

University, hospital or other

Conditions

SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors

Interventions

Vildagliptin

Participants

0

Sites

1

Countries

Germany

Trials that died the same way

• Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery
  “Recruitment insufficient” (96% match in meaning)
• a Randomized Controlled Trial Comparing Medical and Medical-surgical Treatment in Diabetic Foot Osteomyelitis
  “not enough recruitment” (91% match in meaning)
• Study SBX-01-101: A Stool Collection Study in Colorectal Cancer (CRC) Patients Treated With Irinotecan-Based Regimens
  “Insufficient recruitment population.” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.